GAA
NTLA icon

Green Alpha Advisors’s Intellia Therapeutics NTLA Stock Holding History

Green Alpha Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
13,886
-281
-2% -$3.93K 0.16% 95
2026
Q1 		$182K Sell
14,167
-2,526
-15% -$32.2K 0.18% 96
2025
Q4 		$150K Buy
+16,693
New +$230K 0.14% 108
2025
Q3 		– Sell
-11,007
Closed -$103K – 106
2025
Q2 		$103K Sell
11,007
-1,461
-12% -$12K 0.1% 101
2025
Q1 		$88.6K Buy
12,468
+669
+6% +$6.76K 0.09% 104
2024
Q4 		$138K Buy
+11,799
New +$184K 0.11% 139
2024
Q2 		– Sell
-7,964
Closed -$219K – 141
2024
Q1 		$219K Sell
7,964
-2,139
-21% -$59.4K 0.16% 129
2023
Q4 		$308K Sell
10,103
-4,674
-32% -$134K 0.22% 131
2023
Q3 		$467K Sell
14,777
-314
-2% -$12.2K 0.36% 94
2023
Q2 		$615K Buy
15,091
+1,187
+9% +$48.1K 0.4% 96
2023
Q1 		$518K Sell
13,904
-1,467
-10% -$57.5K 0.36% 103
2022
Q4 		$536K Buy
15,371
+813
+6% +$38.7K 0.45% 89
2022
Q3 		$815K Sell
14,558
-67,941
-82% -$4.21M 0.69% 60
2022
Q2 		$4.27M Buy
82,499
+71,748
+667% +$3.64M 0.98% 33
2022
Q1 		$781K Buy
10,751
+1,617
+18% +$137K 0.53% 82
2021
Q4 		$1.08M Buy
9,134
+248
+3% +$31.1K 0.73% 61
2021
Q3 		$1.19M Sell
8,886
-370
-4% -$56K 0.82% 47
2021
Q2 		$1.5M Sell
9,256
-738
-7% -$57.5K 1.02% 34
2021
Q1 		$802K Buy
9,994
+5,255
+111% +$353K 0.79% 53
2020
Q4 		$258K Buy
+4,739
New +$172K 0.31% 90

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Green Alpha Advisors's NTLA Position: Q2 2026 in Review

Green Alpha Advisors reduced its Intellia Therapeutics (NTLA) stake by 2% in Q2 2026, selling an estimated $3.93K and leaving 13,886 shares worth $235K. The position accounts for 0.16% of the portfolio, ranked #95.

Green Alpha Advisors first reported a position in NTLA in Q4 2020 and has held it in 20 quarters since. The position peaked at $4.27M in Q2 2022. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Green Alpha Advisors held 13,886 shares of Intellia Therapeutics worth $235K as of Q2 2026.
  • Green Alpha Advisors sold 281 Intellia Therapeutics shares in Q2 2026, an estimated $3.93K.
  • Intellia Therapeutics made up 0.16% of Green Alpha Advisors's portfolio in Q2 2026, its #95 holding.
  • Green Alpha Advisors first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Green Alpha Advisors's Intellia Therapeutics position peaked at $4.27M in Q2 2022.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.